AI News
Lilly, Profluent Ink Deal on AI Drugs Worth Up to $2.25 Billion
Eli Lilly bets big on generative AI to revolutionize the next generation of precision medicine.
Lilly, Profluent Ink Deal on AI Drugs Worth Up to $2.25 Billion Bloomberg.com
BT
Bloomberg Technology
Source
Bloomberg Technology
AI Analysis
Generated insight by OnAirToday AI
This massive partnership signals a pivotal shift as pharmaceutical giants increasingly rely on generative protein design to accelerate complex drug discovery. By integrating Profluent's AI models, Lilly aims to drastically reduce the traditional timeline for developing therapeutic protein candidates.
Powered by AI • Not a substitute for human analysisMore Insights →
Share
Filed under:AI News

Comments
Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.